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Introduction
The Fas receptor (CD95/APO-1) is a widely expressed
glycosylated cell surface molecule of approximately
45–52 kDa. It is a type I transmembrane receptor and can
also occur in several soluble forms. Under physiological
conditions Fas-mediated apoptosis is triggered by Fas
ligand (FasL/CD95L), the natural ligand of the receptor.
FasL was shown to be a tumour necrosis factor related
type II transmembrane molecule, and its expression is
more restricted than that of Fas [1].
CI = confidence interval; ER = oestrogen receptor; FasL = Fas ligand; PCR = polymerase chain reaction; RT = reverse transcription.
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Abstract
Background: The objective of the present study was to examine the prognostic and predictive
significance of the apoptosis-related marker Fas ligand (FasL):Fas ratio in breast cancer.
Methods: Tumour biopsies from 215 primary invasive breast cancer patients were examined for the
expression of FasL and Fas mRNA transcripts by quantitative real-time RT-PCR. Their prognostic and
predictive impact on patient survival was determined in univariate and multivariate survival analyses.
Results: Using a cutoff value of 1, a FasL:Fas ratio greater than 1 was found to have significant
prognostic value for disease-free survival among the total population (median follow up 54 months). It
was associated with a significantly decreased disease-free survival (P = 0.022) and with a tendency
toward increased mortality (P = 0.14) in univariate analysis. Hormone receptor positive women
exclusively treated with tamoxifen (n = 86) and with a FasL:Fas ratio greater than 1 had a significantly
decreased disease-free survival (P = 0.008) and overall survival (P = 0.03) in univariate Kaplan–Meier
analysis. Furthermore, tumour size and FasL:Fas ratio were of independent predictive significance in
the multivariate model for disease-free and overall survival in that subgroup. Among postmenopausal
patients (n = 148) both of those factors retained independent prognostic significance in the
multivariate model for disease-free survival. In contrast, FasL:Fas ratio had no significant predictive
value in patients exclusively treated with chemotherapy.
Conclusion: The data presented indicate that FasL:Fas ratio may be useful not only as a prognostic
factor but also as a predictive factor for projecting response to the antioestrogen tamoxifen. The results
strongly support a correlation between FasL:Fas ratio greater than 1 and lack of efficacy of tamoxifen
in hormone receptor positive patients.
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FasL is predominantly detected in activated T cells and
activated natural killer cells, but it is also found on some
macrophages/monocytes and on cells of immune privi-
leged tissues [2]. Although there is evidence that some
cancers express FasL on their cell surface, creating an
immune privileged site [3,4], a number of laboratories have
failed to confirm these observations [5,6]. These findings,
in addition to a report that tumours transfected with genes
that express FasL (which was originally predicted to accel-
erate engraftment) were unexpectedly rejected [7], have
confounded interpretation of the earlier studies and the role
of FasL in immune recognition of malignancies [8–10].
In invasive breast carcinomas the expressions of Fas and
FasL appeared to be inversely related [11]. A significant
association was observed between FasL and the pres-
ence of metastatic lymph nodes and larger tumour size,
whereas Fas expression was correlated with node-nega-
tive status and smaller tumour size [12]. Furthermore, high
FasL mRNA and protein expression appears to be posi-
tively correlated with histological grading [13,14], sug-
gesting that a neoplastic Fas-negative/FasL-positive
phenotype may be linked to breast cancer progression.
However, Ragnarsson et al. [15] concluded that FasL is
expressed intracellularly in both normal and malignant
breast epithelium and is unlikely to be important for the
immune evasion of breast tumours.
We previously established the FasL:Fas ratio in tumour
tissue as a prognostic factor in breast carcinomas [14].
An extended follow up allows a re-evaluation of our data-
base regarding the prognostic and predictive value of
FasL:Fas ratio in breast carcinomas. In particular, we
investigated for the first time whether the FasL:Fas ratio
may predict response to cytotoxic or hormonal therapies,
in the same way that the presence of hormone receptors
predicts response to hormonal treatment. Using data
obtained by analysis in various subgroups, the findings
presented here contribute to the recent controversial dis-
cussion on the effects of tumour-expressed FasL in vivo.
Materials and method
Patients and tissue collection
Tissue samples from 215 unselected primary breast carci-
nomas were collected during surgery at the Department of
Obstetrics and Gynaecology of the University of Rostock
between 1994 and 1998. None of the patients had
received chemotherapy, radiotherapy or immunotherapy
before surgery. The mean age for breast cancer patients
was 58 years (range 29–90 years). The majority of breast
tumours (n = 199 [92.5%]) were invasive ductal carcino-
mas. The median follow-up time was 54 months (range
2–77 months).
The main classifying prognostic factors are shown in
Table 1. A total of 200 patients (93%) received post-
operative adjuvant therapy, consisting of chemotherapy
(n = 52), hormone therapy (n = 96), or both (n = 52).
Among patients undergoing endocrine treatment 90 women
(93.7%) were treated with tamoxifen, receiving an oral dose
of 20 mg/day tamoxifen for a maximum of 5 years. Among
the tamoxifen-treated group, we excluded four patients with
hormone receptor negative tumours from further survival
analysis. Of the remaining 86 patients, 41 blood samples
were available for detection of serum oestradiol concentra-
tions using the SR1 enzyme immunoassay (BioChem
Immunosystems GmbH, Freiburg, Germany).
Real-time reverse transcription polymerase chain
reaction
The RT-PCR procedure and preparation of RNA standard
were described previously [14,16]. In brief, total RNA of
freshly frozen breast tissue was prepared in accordance
with the acid guanidium thiocyanate-phenol-chloroform
protocol. All specimens were tested by analysis of glycer-
aldehyde-3-phosphate dehydrogenase housekeeping gene
expression using conventional RT-PCR. First-trimester pla-
centa (FasL) from women undergoing legal abortions and
liver mRNA (Fas) served as positive controls.
The primer pairs and probes were designed using the
Primer Express™ 1.0 program (PE Applied Biosystems,
Foster City, CA, USA) and were obtained from Applied
Biosystems GmbH (Weiterstadt, Germany). The primers
yielded RT-PCR products of 82 (FasL) and 105 (Fas)
nucleotides. For calibration of the FasL and Fas TaqMan™
assays, two RNA standards were generated using an in
vitro  T7-polymerase transcription system (RiboMAX™
Large Scale RNA Production System; Promega, Madison,
WI, USA). The TaqMan® EZ RT-PCR Kit (PE Applied
Biosystems) was used for RT and amplification of both
targets and standards. Production of cDNA and PCR
amplification were carried out in a single-tube, single-
enzyme system, without addition of subsequent enzymes
or buffers. All RT-PCR reactions were performed in dupli-
cate, with a final volume of 25 µl.
Statistical analysis
Clinical, histological and biological parameters were com-
pared using the most appropriate test from among the
Spearman correlation coefficient, χ2 test, Mann–Whitney U
test and Kruskal–Wallis H test. Disease-free and overall
survival were analyzed using the Kaplan–Meier method,
and comparison of study groups was performed using the
log-rank test. The Cox regression model was applied over
both univariate and multivariate analyses, with the associ-
ated likelihood ratio test used for tests of trend differences.
In multivariate analysis, a backward stepwise selection pro-
cedure was used. The Statistical Package for Social
Science (SPSS Inc., Chicago, IL, USA) was used to
conduct statistical analysis. In all tests P < 0.05 was con-
sidered statistically significant and all were two-tailed tests.Page 3 of 6
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Results
Analysis of survival among the total study group
The impact of established prognostic parameters regarding
disease-free and overall survival for the total population is
listed in Table 1. Tumour size (P = 0.001) and lymph node
status (P = 0.009) were significant factors for disease-free
survival, whereas tumour size (P < 0.001) and histological
grading (P = 0.003) were significant prognostic parame-
ters for overall survival within univariate analysis.
Using the cutoff value of 1, a FasL:Fas ratio greater than
1 was found to be a significant prognostic factor for
disease-free survival in the present update analysis. It was
associated with a significantly decreased disease-free sur-
vival (P = 0.022; Fig. 1a) and with a tendency toward
increased mortality (P = 0.14; Fig. 1b). The mean disease-
free survival time for patients with a ratio of 1 or less was
67 months (95% confidence interval [CI] 63–70 months)
versus 59 months (95% CI 53–65 months) for patients
with a ratio greater than 1.
All variables that achieved significance in the univariate
survival analysis were incorporated in a multivariate analy-
sis (Table 2). Tumour size (P = 0.004) and lymph node
status (P = 0.04) were of independent significance in the
multivariate disease-free survival analysis (n = 208).  Fur-
thermore, tumour size (P = 0.001) and grading
(P = 0.023) were independent prognostic parameters for
overall survival in the multivariate model (n = 208).
Analysis of survival among tamoxifen-treated patients
Ideally, a predictive factor should be evaluated only in the
setting of individuals who have not received different sys-
temic therapies. For this reason we divided the total popu-
lation into hormone receptor positive tamoxifen-treated
(n = 86) and chemotherapy-treated (n = 52) subgroups.
Among the tamoxifen-treated subgroup 75 patients
(83.3%) were node negative. The FasL:Fas ratio values
were positively correlated with histological grading
(P = 0.048) and serum oestradiol concentrations
(P = 0.04). Women with a FasL:Fas ratio greater than 1
had significantly higher serum oestradiol levels than did
women with a FasL:Fas ratio of 1 or less (P = 0.002). No
associations between FasL:Fas ratio and other factors
such as tumour size (P = 0.129), lymph node status
(P = 0.378), age (P = 0.822), body mass index
(P = 0.174) and use of exogenous hormones (P = 0.732)
were observed.
Available online http://breast-cancer-research.com/content/4/5/R9
Table 1
Clinicopathological characteristics of 215 breast cancer patients and univariate analysis of established prognostic factors for
disease-free and overall survival
Disease-free survival Overall survival
Factor Number of patients (%) P RR (95% CI) P RR (95% CI)
Menopausal status (n = 209)
Premenopausal 62 (29.7) 0.121 1.73 (0.86–3.47) 0.061 2.49 (0.96–6.45)
Postmenopausal 147 (70.3)
Histological grading (n = 206)
I 101 (49.0) 0.113 1.36 (0.93–2.0) 0.003 1.93 (1.25–3.0)
II 81 (39.3)
III 24 (11.7)
Lymph node status (n = 203)
Negative 116 (57.1) 0.009 2.22 (1.22–4.03) 0.095 1.85 (0.9–3.82)
Positive 88 (42.9)
Tumour size (n = 205)
pT1 93 (45.4) 0.001 1.85 (1.29–2.65) <0.001 2.3 (1.53–3.45)
pT2 96 (46.8)
pT3 and pT4 16 (7.8)
Oestrogen receptor status (n = 208)
≤10 fmol/mg 74 (35.6) 0.73 1.12 (0.58–2.16) 0.547 1.29 (0.56–2.99)
>10 fmol/mg 134 (64.4)
Progesterone receptor status (n = 205)
≤10 fmol/mg 118 (57.6) 0.056 0.57 (0.33–1.01) 0.636 0.84 (0.42–1.67)
>10 fmol/mg 87 (42.4)
Fas ligand : Fas ratio (n = 211)
≤1 139 0.023 1.92 (1.09–3.35) 0.172 1.61 (0.81–3.2)
>1 72
CI, confidence interval; RR, relative risk.Women exclusively treated with tamoxifen (n = 86) and
with a FasL:Fas ratio greater than 1 had a significantly
decreased disease-free survival (P = 0.0084) and overall
survival (P = 0.03) on univariate Kaplan–Meier analysis
(Fig. 2). The mean disease-free survival time for tamoxifen-
treated patients with a ratio of 1 or less was 71 months
(95% CI 67–75 months) versus 57 months (95% CI
48–67 months) for patients with a ratio greater than 1.
The corresponding data for overall survival were
74 months (95% CI 70–77 months) for a ratio of 1 or less
and 66 months (95% CI 58–73 months) for a ratio greater
than 1. Tumour size (P = 0.013) and FasL:Fas ratio
(P = 0.013) were significantly related to reduced disease-
free survival in univariate Cox regression analysis
(Table 3). Tumour size (P = 0.023) and FasL:Fas ratio
(P = 0.027) were also of independent prognostic signifi-
cance in the multivariate model (n = 86). The relative risk
for occurrence of breast cancer related relapse in tamox-
ifen-treated patients was 3.0 (95% CI 1.14–7.9) for
women with a FasL:Fas ratio greater than 1.
Corresponding analyses for overall survival in tamoxifen-
treated patients revealed prognostic impact of tumour size
(P = 0.002), tumour grading (P = 0.015) and FasL:Fas
ratio (P = 0.042) in the univariate setting. The multivariate
analysis confirmed all three of those parameters as inde-
pendent markers for overall survival in tamoxifen-treated
patients (Table 3).
Analysis of survival among postmenopausal patients
The tamoxifen-treated subgroup (age range 50–90 years)
comprised 94.5% postmenopausal and 5.5% pre-
menopausal patients, and we therefore re-analyzed the
data for the postmenopausal population (n = 149). On
univariate Kaplan–Meier analysis, postmenopausal women
with a FasL:Fas ratio greater than 1 had decreased
Breast Cancer Research    Vol 4 No 5 Reimer et al.
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Figure 1
(a) Disease-free and (b) overall survival curves for breast cancer patients (n = 211) with respect to Fas ligand (FasL):Fas ratio. Survival was
analyzed using the Kaplan–Meier method, and comparison of study groups was performed using the log-rank test.
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Table 2
Multivariate Cox regression analysis for disease-free and overall survival, including prognostic factors that were significant on
univariate analysis
Disease-free survival Overall survival
Variable P RR (95% CI) P RR (95% CI)
Histological grading – – 0.023 1.68 (1.07–2.62)
Lymph node status 0.04 1.9 (1.03–3.49) – –
Tumour size 0.004 1.77 (1.2–2.6) 0.001 2.1 (1.38–3.2)
Fas ligand:Fas ratio 0.161 1.52 (0.85–2.73) – –
The analysis was conducted in 208 women. CI, confidence interval; RR, relative risk.disease-free survival (P = 0.01) and overall survival
(P = 0.182) as compared with postmenopausal women
with a ratio of 1 or less (Fig. 3). The mean disease-free
survival time for postmenopausal patients with a ratio of 1
or less was 67 months (95% CI 62–71 months) versus
56 months (95% CI 49–63 months) for patients with a
ratio greater than 1. The corresponding data for overall
survival were 69 months (95% CI 65–73 months) and
65 months (95% CI 59–71 months), respectively. Tumour
size (P = 0.001) and FasL:Fas ratio (P = 0.01) were sig-
nificantly related to reduced disease-free survival on uni-
variate Cox regression analysis (Table 4).
Both factors (tumour size P = 0.003; FasL:Fas ratio
P = 0.028) retained independent prognostic significance
in the multivariate model (n = 148). The relative risk for
occurrence of breast cancer related relapse in post-
menopausal patients was 2.04 (95% CI 1.14–7.36) for
women with a ratio greater than 1. Among the post-
menopausal subgroup no associations between FasL:Fas
ratio and other factors such as tumour size (P = 0.096),
tumour grading (P = 0.108), lymph node status
(P = 0.339), age (P = 0.55), oestrogen receptor (ER;
P = 0.741), progesterone receptor (P = 0.748), body
mass index (P = 0.92) and use of exogenous hormones
(P = 0.26) were observed.
Analysis of survival among patients undergoing
cytotoxic therapy
In contrast to the findings summarized above, FasL:Fas
ratio had no significant prognostic value in patients treated
exclusively with chemotherapy. Using Kaplan–Meier analy-
sis, disease-free (P = 0.94) and overall survival
(P = 0.765) were not related to FasL:Fas ratio. Similarly,
Available online http://breast-cancer-research.com/content/4/5/R9
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Figure 2
(a) Disease-free and (b) overall survival curves for tamoxifen-treated, hormone receptor positive breast cancer patients (n = 86) with respect to Fas
ligand (FasL):Fas ratio. Survival was analyzed using the Kaplan–Meier method, and comparison of study groups was performed using the log-rank test.
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Table 3
Cox regression analysis for disease-free and overall survival in tamoxifen-treated, hormone receptor positive patients
Disease-free survival analysis Overall survival analysis
Univariate Multivariate Univariate Multivariate
Variable P RR (95% CI) P RR (95% CI) P RR (95% CI) P RR (95% CI)
Grading 0.151 1.7 (0.82–3.16) – – 0.015 2.81 (1.22–6.5) 0.025 2.69 (1.13–6.4)
Lymph node status 0.284 1.89 (0.59–6.03) – – 0.055 3.81 (1.02–14.3) – –
Tumour size 0.013 2.25 (1.18–4.26) 0.023 2.24 (1.12–4.5) 0.002 3.43 (1.56–7.56) 0.005 3.83 (1.51–9.72)
FasL : Fas ratio 0.013 3.4 (1.29–8.96) 0.027 3.0 (1.14–7.9) 0.042 3.59 (1.05–12.3) 0.043 3.65 (1.04–12.8)
The analysis was conducted in 86 women. CI, confidence interval; FasL, Fas ligand; RR, relative risk.no significant associations were found between FasL:Fas
ratio and survival time in premenopausal patients (data not
shown).
Recurrence pattern
Because of the significance of FasL:Fas ratio for disease-
free survival in postmenopausal or tamoxifen-treated
women, we analyzed the pattern of locoregional and distant
relapse. Among the 149 postmenopausal patients, 39
(26.2%) had recurrent disease. The relapse rate was
39.3% (n = 22) in 56 patients with a ratio greater than 1
and 18.3% (n = 17) in 93 women with a ratio of 1 or less.
Skeletal (41.2%) and pulmonary metastases (23.5%), and
locoregional progression (23.5%) were frequently observed
in postmenopausal patients with a ratio of 1 or less. Liver
(33.3%) and skeletal metastases (22.2%), and locoregional
progression (22.2%) occurred predominantly in patients
with a ratio greater than 1. However, no specific recurrence
patterns were detected with respect to FasL:Fas ratio.
Discussion
At present there are only two factors with clinical level 1
evidence supporting a predictive role for response to
breast cancer therapy. First, optimal adjuvant hormonal
therapy is 5 years of tamoxifen for anyone with a tumour
that is hormone receptor positive, even if at a low level.
Breast Cancer Research    Vol 4 No 5 Reimer et al.
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Figure 3
(a) Disease-free and (b) overall survival curves for postmenopausal breast cancer patients (n = 149) with respect to Fas ligand (FasL):Fas ratio.
Survival was analyzed using the Kaplan–Meier method, and comparison of study groups was performed using the log-rank test.
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Table 4
Cox regression analysis for disease-free and overall survival in postmenopausal patients
Disease-free survival analysis Overall survival analysis
Univariate Multivariate Univariate Multivariate
Variable P RR (95% CI) P RR (95% CI) P RR (95% CI) P RR (95% CI)
Grading 0.107 1.42 (0.93–2.17) – – 0.015 1.81 (1.12–2.91) 0.059 1.58 (0.98–2.56)
Lymph node status 0.05 1.97 (1.01–3.87) – – 0.134 1.83 (0.83–4.05) – –
Tumour size 0.001 1.85 (1.27–2.7) 0.003 1.79 (1.22–2.64) 0.001 2.11 (1.38–3.23) 0.002 1.97 (1.27–3.03)
ER status 0.774 1.12 (0.53–2.34) – – 0.903 0.95 (0.4–2.24) – –
PgR status 0.19 0.65 (0.34–1.23) – – 0.558 0.8 (0.37–1.7) – –
FasL : Fas ratio 0.01 2.29 (1.22–4.32) 0.028 2.04 (1.08–3.85) 0.187 1.65 (0.78–3.46) – –
The analysis was conducted in 148 women. CI, confidence interval; ER, oestrogen receptor; FasL, Fas ligand; PgR, progesterone receptor; RR,
relative risk.Patients whose cancers express neither ER nor proges-
terone receptor will not be helped by tamoxifen administra-
tion [17]. Second, recent data suggest that adjuvant
treatment with trastuzumab will prove ineffective for
tumours with low levels of HER-2/neu expression [18].
The new data presented here indicate that the FasL:Fas
ratio may be useful not only as a prognostic factor but also
as a predictive factor for projecting response to the
antioestrogen tamoxifen. In patients with hormone recep-
tor positive primary tumours, a FasL:Fas ratio greater than
1 defines a subgroup of patients who are less likely to
respond to tamoxifen. Women exclusively treated with
tamoxifen and with a FasL:Fas ratio greater than 1 had a
14-month shorter mean disease-free survival and a relative
risk of 3.0 for relapse of disease as compared with
patients with a FasL:Fas ratio of 1 or less. Furthermore, a
ratio greater than 1 was associated with a significantly
shorter overall survival (P = 0.043) and a relative risk for
death of 3.65 in that subgroup. No correlation was seen
between FasL:Fas ratio and survival time in patients
receiving cytotoxic treatment.
The unexpected finding that FasL:Fas ratio is a prognos-
tic factor in postmenopausal and a predictive factor in
tamoxifen-treated patients may be accounted for by
hormone dependency. Various studies suggest that the
FasL/Fas system may play an important role in the regula-
tion of cell death in response to hormonal changes. Nilsen
et al. [19] showed that oestrogen induces apoptosis in
neurone-like cells that express ER-β, and that this is medi-
ated by the FasL/Fas system. Selam et al. [20] suggested
that oestradiol and progesterone may play a role in regu-
lating maternal immunotolerance for the implantation of a
semiallograft embryo by inducing FasL expression in
human endometrium. Recent findings support the hypothe-
sis that oestrogen-induced thymic atrophy occurs as a
result of apoptosis and is mediated by oestrogen-induced
FasL expression [21]. Finally, maintenance of endothelial
FasL expression by oestradiol may represent a mechanism
for the apparently antiatherogenic effect of oestrogen [22].
Novel findings further link the FasL/Fas system and hor-
mones such as oestrogen and lactogenic hormones to the
biology of the normal mammary gland and the develop-
ment of breast cancer [23]. Treatment of LTED cells,
which were derived by growing MCF-7 breast cancer cells
under long-term oestrogen-deprived conditions, with
oestradiol increased the expression of FasL [24]. Mor et
al. [25] showed that FasL in breast tissue is functionally
active, and that oestrogen and tamoxifen regulate its
expression. Those investigators identified an oestrogen-
recognizing element-like motif in the promoter region of
the FasL gene, suggesting direct effects of oestrogen on
FasL expression. This effect is receptor mediated because
tamoxifen blocked the oestrogenic effect.
The indication for use of antioestrogens in mammary carci-
noma arises from the observations that oestrogen is a
mitogen in breast cancer and that approximately one-third
of patients will respond to endocrine therapy. The main
therapeutic antioestrogen that has been used is tamoxifen.
The present data indicate that the antitumour effect of
tamoxifen varies according to the FasL:Fas ratio of the
breast tumour, and values of the ratio are positively corre-
lated to serum oestradiol levels. The use of tamoxifen in
patients with a FasL:Fas ratio greater than 1 is less effec-
tive than in those with higher ratios, leading to the hypo-
thesis that the recently developed aromatase inhibitors
anastrozole, letrozole and exemestan are more appropriate
in these patients, or that additional cytotoxic treatment will
be of benefit in this subgroup.
The role of FasL expressed by breast tumour in the induc-
tion of apoptosis of infiltrating Fas-expressing immune
cells, and thereby conferring immune privilege on the
tumour, is at present unclear [8,10]. The expression of
FasL by tumours implies not only that cancers have
acquired defensive strategies (Fas resistance) but also
that they can take the offensive (counterattack) [26,27].
On the basis of the findings presented here, we hypothe-
size that the association between high-FasL/low-Fas
phenotype and shorter disease-free survival in older breast
carcinoma patients may be due to a decline in immune
function, which results in increased escape of tumour cells
from immune surveillance.
Of special interest are age-related changes in tumour-
infiltrating lymphocytes. Cytotoxic lymphocytes from aged
mice are less able to bind targets, although they appear
to be equally effective in destroying their targets [28].
Assuming that FasL-positive tumour cells interact with
tumour-infiltrating lymphocytes, our clinical data support
indirectly the counterattack model. Immune surveillance
among older patients is insufficient in breast carcinomas
with a FasL:Fas ratio greater than 1, which leads to an
increased rate of locoregional or distant metastases and
to a shorter disease-free survival in postmenopausal
patients. However, there is little evidence to support direct
causal links between immune senescence and most
malignancies, although data from in vitro and  in vivo
animal and human studies demonstrate clear age-related
alterations in both cellular and humoral components of the
immune system [29].
Conclusion
The present findings confirm the prognostic significance
of FasL:Fas ratio in breast carcinoma in a re-evaluated
database over 54 months of follow up. Particularly in post-
menopausal patients, the FasL:Fas ratio retained inde-
pendent prognostic significance in multivariate analysis for
disease-free survival. Additionally, the data strongly
support a correlation between FasL:Fas ratio greater than
Available online http://breast-cancer-research.com/content/4/5/R9
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positive patients. However, given the important therapeu-
tic repercussions of this issue, further studies are required
before evaluation of FasL:Fas ratio can be routinely used
to select patients who are likely to benefit from tamoxifen
administration.
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